LUNGevity Foundation is pleased to offer funding in the following translational research awards in 2024.

  • The Brown/LUNGevity Award to Understand Mechanisms of Resistance to Immunotherapy will fund high-impact research that seeks to understand resistance to first-line immunotherapy and develop therapeutic strategies targeting this resistance. This is a $500,000, two-year award.
    Learn more

 

  • LUNGevity’s Career Development Award supports future research leaders who will keep the field of lung cancer research vibrant with new ideas. Research that will be funded in 2024 is expected to have a direct impact on the early detection of lung cancer and/or individualized lung cancer treatment, including through targeted therapy and immunotherapy. This is a mentored, three-year, $300,000 award.
    Learn more

 

  • The Hamoui Foundation/LUNGevity Clinical Research Award for RET-positive Lung Cancer supports high-impact research seeking to transform the future for people diagnosed with RET-positive lung cancer. Projects funded through this program are expected to have a direct impact on the outcomes of patients with advanced RET-positive lung cancer, but innovative proposals that address other unmet needs in the RET-positive lung cancer space are also invited for submission. This is a $500,000, two-year award.
    Learn more

 

  • The RETpositive/LUNGevity Translational Research Award for RET-positive Cancer will fund high-impact research that seeks to transform the future for patients diagnosed with RET-positive cancers by changing RET-positive cancers into a chronic or curable condition. Proposals focusing on multiple types of RET-positive cancers or with a clear impact on multiple types of RET-positive cancers will be given priority. This is a two-year, $100,000 award.
    Learn more

 

  • The Rising Tide/LUNGevity Team Award to Target Mechanisms of Resistance will fund high-impact interventional clinical trials that seek to develop therapeutic strategies targeting shared mechanisms of resistance in oncogene-driven lung adenocarcinoma (LUAD). Projects funded are expected to further our knowledge of shared mechanisms of resistance across oncogene-driven LUAD and how they can be targeted using novel pharmaceutical agents (monotherapies or combination therapies). The program has no geographical restrictions and is open to both US and non-US applicants. This is a $1,500,000, three-year team award; the involvement of at least two institutions is required.
    Learn more